Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 1365, GRK 2318, FOR 2841, HI-2238/2-1, SFB-TR 84, B6 / Z1a, EN 924/5-1, RA 838/5-1, KA 5006/1-1, Gottfried Wilhelm Leibniz Prize)
Berlin Institute of Health (Focus Area Translational Vascular Biomedicine, COVID Startup funding)
Berlin University Alliance GC2 Global Health (Corona Virus Pre-Exploration Project)
Bundesministerium für Bildung und Forschung ((RAPID, Organo-Strat 01KX2021)
Dr. Werner Jackstädt-Stiftung
Received: 11 January 2022
Accepted: 12 August 2022
First Online: 9 September 2022
: Our study protocol was approved by Charité’s Ethics Committee (ethics approvals EA2/045/18 for post mortem kidney biopsies and EA4/026/18 for tumor-adjacent normal tissue) and was conducted by following the Declaration of Helsinki and Guidelines for Good Clinical Practice. Written informed consent was given by the next of kin before enrollment in our study.
: Not applicable.
: The authors declare no competing interests.